Boston moves to limit coverage of GLP-1 weight-loss drugs and other high-cost prescriptions for employees

What is changing and why it matters

Boston is preparing to tighten prescription-drug coverage for city employees, with particular attention on GLP-1 medications that have become widely used for weight loss. The move reflects a broader shift across Massachusetts employers and insurers to constrain rapidly rising pharmacy spending tied to GLP-1s and other high-cost therapies.

GLP-1 drugs include products such as Wegovy and Zepbound for obesity and Ozempic and Mounjaro for type 2 diabetes. Health plans have increasingly distinguished between coverage for diabetes treatment—often retained—and coverage for weight management, which has been more frequently reduced or excluded as plan sponsors seek to control premiums and overall claims costs.

How insurer policy changes shape employer decisions

Large insurers operating in Massachusetts have revised standard benefit designs for 2026, with GLP-1 coverage for weight loss no longer included by default in many plans. Instead, employers may be offered an option to “buy back” weight-loss coverage through plan riders or other add-ons that can increase premiums. For employers with renewal dates later in the year, benefit changes may take effect at the start of the new plan year rather than on January 1.

For municipal employers, the timing is especially important because many public-sector health plans renew on July 1, meaning any changes adopted in 2026 could begin with the fiscal-year plan cycle.

Public-sector pressure is increasing statewide

The city’s action comes as Massachusetts’ state employee health plan has moved to eliminate coverage of GLP-1 drugs when prescribed strictly for weight management. That change, set to apply beginning with the next plan year, was framed as a cost-containment measure amid concern that GLP-1 utilization is expanding faster than budgets and premiums can absorb.

State officials have also emphasized that GLP-1 spending is only one component of pharmacy inflation, but it has become a defining issue because of the drugs’ high monthly costs and the potential for long-term use.

What employees could experience

If Boston proceeds with curbs on GLP-1 coverage for weight loss, affected employees and dependents could face:

• Exclusions for weight-loss indications while maintaining coverage for type 2 diabetes.
• Tighter prior authorization rules and clinical criteria for continued coverage.
• Higher out-of-pocket costs if coverage is removed or restricted.
• Plan design changes affecting other expensive drug categories, depending on the final package adopted.

Across Massachusetts, public and private employers have been reassessing GLP-1 coverage as insurers redesign benefits and seek new approaches to affordability.

What to watch next

Key details—such as which specific drugs are affected, whether exceptions will be allowed, and what alternative programs or coverage options may be offered—will depend on final plan design decisions and renewal negotiations. The practical impact on employees will also hinge on effective dates tied to Boston’s plan year and on whether the city opts to purchase additional coverage to maintain access for weight management.

For city workers currently using GLP-1 medications, the next open enrollment and renewal cycle will be the critical window for benefit updates, transition rules, and any continuity-of-care provisions.